Skip to main content
ROSSARI BIOTECH LIMITED logo

ROSSARI BIOTECH LIMITED — Investor Relations & Filings

Ticker · ROSSARI ISIN · INE02A801020 LEI · 335800R7XFRR8ZTHBQ25 BSE.NS Manufacturing
Open in API
Filings indexed 526 across all filing types
Latest filing 2025-01-31 Regulatory Filings
Country IN India
Listing BSE.NS ROSSARI

About ROSSARI BIOTECH LIMITED

https://www.rossari.com/

Rossari Biotech Limited is a specialty chemicals manufacturer focused on providing sustainable and innovative solutions across diverse sectors. The company operates through three primary business segments: Home, Personal Care and Performance Chemicals (HPPC), Textile Specialty Chemicals, and Animal Health and Nutrition. In the HPPC segment, it supplies essential ingredients for detergents, soaps, paints, and water treatment applications. Its textile division offers a comprehensive range of chemicals for the entire textile value chain, including pre-treatment, dyeing, and finishing processes. Additionally, the company provides high-quality feed additives and supplements for the poultry and livestock industries. Driven by robust research and development capabilities, Rossari Biotech emphasizes eco-friendly chemistry and customized formulations to meet specific client requirements. With advanced manufacturing facilities, the company serves a global clientele, maintaining a strong focus on operational excellence.

Recent filings

Filing Released Lang Actions
Action(s) taken or orders passed
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding an update on a regulatory appeal outcome under SEBI Listing Regulations. It references compliance with Regulation 30, which pertains to disclosure obligations for listed companies. The content is an intimation about a favorable order received from a tax authority appeal, not a financial report or detailed filing. The document length is short (1865 characters) and it serves as a notification of a regulatory event rather than a full report or financial statement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance disclosures that do not fit other specific categories.
2025-01-31 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings conference call held on January 23, 2025, for the third quarter of fiscal year 2025 (Q3 FY25). It includes opening remarks from the management, financial performance details, business segment updates, strategic initiatives, and a question-and-answer session with analysts. The content is typical of a full earnings call transcript, providing comprehensive discussion of quarterly financial results and business outlook. The document is lengthy (15,000 characters) and contains substantive financial data and management commentary, which aligns with the definition of a Call Transcript (CT). It is not merely an earnings release (ER) which would be a brief announcement of key financial highlights, nor is it an Annual Report or Interim Report. The presence of Q&A further confirms it is a call transcript. Therefore, the appropriate classification is Call Transcript (CT).
2025-01-28 English
Integrated Filing- Financial
Regulatory Filings
2025-01-28 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short letter notifying the stock exchanges about the availability of the audio recording of the earnings conference call for Q3 FY25. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) and provides a link to the recording on the company's website. The document does not contain any financial data or detailed transcript but is an announcement about the earnings call recording. Given the short length (1286 characters) and the nature of the content, this fits best as a Regulatory Filing (RNS) rather than a full Call Transcript (CT) or Earnings Release (ER).
2025-01-23 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated January 22, 2025, announcing the financial results for the quarter and nine months ended December 31, 2024 (Q3 FY25). It contains detailed financial performance data including revenues, EBITDA, PAT, EPS, and segment growth comparisons year-over-year. It also includes management commentary on the results and key developments such as capacity expansion projects. The document is not a full annual or interim report but a summary announcement of quarterly financial results. This matches the definition of an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results with key highlights. The document length (8429 characters) and content confirm it is a full earnings release rather than a brief announcement or a regulatory filing. Therefore, the correct classification is ER with high confidence. Q3 2025
2025-01-22 English
Investor Presentation
Regulatory Filings
2025-01-22 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.